Skip to ContentSkip to Navigation
Practical matters How to find us A. Visser

Research interests

Lydia Visser received a PhD from the University of Groningen, the Netherlands in 2000 on her thesis titled: ‘Antibodies against leucocyte common antigen (CD45)-applications in immunomodulation’. She subsequently held a post-doctoral position at the Robards Research Institute of the University of Western Ontario in London (Ontario, Canada) on a project on the mechanism of anti-CD45RB tolerance induction. She is currently working at the department of Pathology and Medical Biology of the University Medical center Groningen as a scientist. She is as a PI part of the SALL. Her research is mainly focussed on the immunology of lymphoma and consists of interactions of tumor cells with the micro environment and signalling pathways in Hodgkin lymphoma and non-Hodgkin lymphomas.

 

Publications

A gene expression-based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma

Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro

CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2: Characterizing CD4+ T cells in Hodgkin lymphoma

Cytochrome P450 27C1 Level Dictates Lung Cancer Tumorigenicity and Sensitivity towards Multiple Anticancer Agents and Its Potential Interplay with the IGF-1R/Akt/p53 Signaling Pathway

Identification of the estrogen receptor beta as a possible new tamoxifen-sensitive target in diffuse large B-cell lymphoma

Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP

Site-Directed Mutants of Parasporin PS2Aa1 with Enhanced Cytotoxic Activity in Colorectal Cancer Cell Lines

Validation of Novel Molecular Imaging Targets Identified by Functional Genomic mRNA Profiling to Detect Dysplasia in Barrett’s Esophagus

Computational study, synthesis and evaluation of active peptides derived from Parasporin-2 and spike protein from Alphacoronavirus against colon cancer cells

Genetic Modification Approaches for Parasporins Bacillus thuringiensis Proteins with Anticancer Activity

Read more